ShareValue scores for 0JW9.LSE: Valuation 38, Quality 24, Growth 51, Health 51.
0JW9.LSELSE
MEI Pharma Inc.
£0.01
(-0.02%)
0JW9.LSELSE
MEI Pharma Inc.
£0.01(-0.02%)
Loading chart...
Sentiment
Verdicts
Value:Overvalued
Quality:Weak
Growth:Moderate
Health:Moderate
Verdicts
Fundamental Rating
Value Trap Risk
Expected Return
-7% to 12%
Rating
Trap Risk
Return
-7% to 12%
Valuation
38
Overvalued
Price vs Value
Quality
24
Weak
Business Strength
Growth
51
Moderate
Revenue & Earnings
Health
51
Moderate
Financial Stability
Momentum
20
Bearish
Price Trend
Company Details
About
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.
Sector
IndustryN/A
ExchangeLSE
Market Cap$690,627.63
P/E RatioN/A
Dividend YieldNone
Sector Rank#2040
Score Analysis
AI Investment Thesis
Data as of:Aug 7, 2026
|Last calculated:Aug 7, 2026